Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549595 · ClinicalTrials.gov registry record · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
A Phase 3 study of Untreated Follicular Lymphoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,018
- Enrollment target
- 20
- Study locations
NCT06549595 is a Phase 3 study of Untreated Follicular Lymphoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,018 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT06549595, a Phase 3 study of Untreated Follicular Lymphoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,018 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.
Conditions Studied
Interventions
- DRUG Surovatamig
- DRUG R-CHOP
- DRUG R-CVP
- DRUG BR
Study Locations (20)
Other
- Research Site - Garran
- Research Site - Heidelberg
- Research Site - Macquarie University
- Research Site - Nedlands
- Research Site - Brussels
- Research Site - Brussels
- Research Site - Ghent
- Research Site - Mechelen
- Research Site - Porto Alegre
- Research Site - São Paulo
- Research Site - São Paulo
New York
- Research Site - New York
- Research Site - New York
Alaska
- Research Site - Anchorage
Colorado
- Research Site - Aurora
Connecticut
- Research Site - New Haven
Michigan
- Research Site - Ann Arbor
Tennessee
- Research Site - Nashville
Manitoba
- Research Site - Winnipeg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,018 participants |
| Start Date | 2024-08-07 |
| Est. Completion | 2031-11-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06549595
The ClinicalTrials.gov registry entry for NCT06549595 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,018 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Untreated Follicular Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Surovatamig is the first listed.
NCT06549595 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, New York, Alaska.
Frequently Asked Questions
What is clinical trial NCT06549595 about?
NCT06549595 is a clinical study titled "A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients". This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with un...
What is the current status of trial NCT06549595?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,018 participants. The study started on 2024-08-07. Estimated completion is 2031-11-26.
What conditions does trial NCT06549595 study?
This clinical trial studies the following conditions: Untreated Follicular Lymphoma.
What interventions are being tested in trial NCT06549595?
The interventions under investigation include: Surovatamig (DRUG), R-CHOP (DRUG), R-CVP (DRUG), BR (DRUG).
Who is sponsoring clinical trial NCT06549595?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06549595 being conducted?
This trial has 20 study locations across Alaska, Colorado, Connecticut, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.